## CDNA: CareDx, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 10.1% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($18.04)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.1%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +3.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 22.7x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.1B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.7 |
| Current P/E | 28.8 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 6.5% to 10.1% (+3.6% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (10.1% > 10.0%), caution on chasing. MRS_5 at 3.1% confirms short-term momentum alignment. AM_20 at 12.4% shows strong absolute momentum above own 20MA. Outperforming sector by 12.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 10.08% (CS: 94) | Strong |
| RSI_14 | 68.6 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.124x | Above |
| vs SMA50 | 1.233x | Above |
| vs SMA200 | 1.210x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $19.80
- **Stop Loss:** $18.04 (8.9% risk)
- **Target:** $21.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 784
- **Position Value:** $15,523.20
- **Portfolio %:** 15.52%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*